Symbol="KROS"
AssetType="Common Stock"
Name="Keros TherapeuticsÂ Inc"
Description="Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts."
CIK="1664710"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="99 HAYDEN AVENUE, SUITE 120 (BLD E), LEDGEMONT TECHNOLOGY CENTER, LEXINGTON, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="1149642000"
EBITDA="-128805000"
PERatio="None"
PEGRatio="None"
BookValue="12.01"
DividendPerShare="0"
DividendYield="0"
EPS="-4.21"
RevenuePerShareTTM="0.824"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.261"
ReturnOnEquityTTM="-0.402"
RevenueTTM="20000000"
GrossProfitTTM="-87265000"
DilutedEPSTTM="-4.21"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="95"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="68.42"
PriceToBookRatio="5.74"
EVToRevenue="57.24"
EVToEBITDA="-14.45"
Beta="1.084"
num_52WeekHigh="59.96"
num_52WeekLow="27.57"
num_50DayMovingAverage="44.11"
num_200DayMovingAverage="46.39"
SharesOutstanding="29584200"
DividendDate="None"
ExDividendDate="None"
symbol="KROS"
open="39.19"
high="40.16"
low="38.81"
price="40.12"
volume="98170.00"
latest_trading_day="2023-07-12"
previous_close="38.86"
change="1.26"
change_percent="3.2424%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="76"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="24"
Volume_recent_avg="226086"
Change_recent_avg="-0.12"
Delta_recent_avg="2.34"
Variance_recent_avg="1.17"
Change_ratio_recent_avg="-0.32"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="24"
Aroon_momentum_negative="76"
image_negative_thumbnail_id_1="1150"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0183.jpeg"
image_negative_thumbnail_id_2="151"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0025.jpeg"
image_neutral_thumbnail_id_1="591"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0008.jpeg"
image_neutral_thumbnail_id_2="521"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0078.jpeg"
image_positive_thumbnail_id_1="601"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0107.jpeg"
image_positive_thumbnail_id_2="636"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0072.jpeg"
image_professor_thumbnail_id_1="1176"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0010.jpeg"
image_professor_thumbnail_id_2="1201"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0035.jpeg"
